# Deep Learning for Biopsy-Free Subtyping of Basal Cell Carcinoma from Dermatoscopic Images

arXiv: https://arxiv.org/abs/2609.07180 · HTML: https://mlsanity.com/paper/2609.07180/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 3 of its 18 references that are in the map.
- First posted on arXiv 7 Sep 2026.

## Builds on (most cited first, 3 of 3)

- [An Image is Worth 16x16 Words: Transformers for Image Recognition at Scale](https://mlsanity.com/paper/2010.11929/) (2020)
- [BEiT: BERT Pre-Training of Image Transformers](https://mlsanity.com/paper/2106.08254/) (2021)
- [Single Model Deep Learning on Imbalanced Small Datasets for Skin Lesion Classification](https://mlsanity.com/paper/2102.01284/) (2021)

## Abstract (arXiv)

Basal Cell Carcinoma (BCC) is the most common type of skin cancer, accounting for nearly 80% of skin cancer di- agnoses. Its optimal clinical management is guided by the distinct histopathologic subtype, with aggressive variants requiring more drastic measures. In current clinical practice, subtyping relies on skin biopsies, a procedure both costly and invasive. In this paper, we conduct a preliminary investigation into using deep learning for BCC subtyping, solely from a single dermatoscopic image of the lesion. Given the limited data at our disposal, we employ pre-trained vision transformers (ViTs), a state-of-the-art family of models highly effective for challenging downstream tasks with limited labeled data. Through repeated stratified k-fold cross-validation, we demonstrate that ViTs can achieve superior performance (AUC 0.784 on a dataset of 1271 dermatoscopic images of various BCC subtypes) over standard CNN-based baselines as well as previously-reported human reader perfor- mance, on the task of differentiating aggressive BCCs from other subtype families. These initial findings highlight the potential of combining deep learning and dermatoscopy to provide a biopsy- free alternative for BCC subtyping, thus aiding in improving treatment planning and patient outcomes.